In the pivotal ALCANZA trial, BV demonstrated significantly superior efficacy to standard treatments in CD30-positive MF, with a 56% ORR4 and improved progression-free survival [50,51]. This evidence concerns the gene TNFRSF8 and mycosis fungoides.